ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions
Jump to:  View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 2613
    Ga-FAPI-04 PET/CT reveals increased fibroblast activation in synovial and enthesial tissues of psoriasis patients with arthralgia and predicts the development of psoriatic arthritis
  • Abstract Number: 2096
    Gamification and Social Incentivization to Promote Physical Activity in Adults with Knee Osteoarthritis: Results from a Multi-Site Randomized Trial
  • Abstract Number: 0527
    Gaps In Documentation Of Psoriatic Arthritis Domains In General Rheumatologic Practices Compared To Rheumatology-Dermatology Combined Clinics
  • Abstract Number: 1558
    Gastrointestinal Symptom Severity Is Associated With Worse Patient-Reported Outcomes And Dietary Patterns In Systemic Sclerosis: A Single Center Prospective Study
  • Abstract Number: 1291
    Gastrointestinal Tract Involvement in Juvenile Systemic Sclerosis: Results from an International Scoping Review of Outcome Measures
  • Abstract Number: 0326
    Gender Disparities in Clinical Outcomes Among Older Adults with Knee Osteoarthritis: A Retrospective Cohort Study
  • Abstract Number: 1180
    Gender-Based Clinical Differences in Behçet’s Syndrome: Findings from a 24-Year Cohort in a Non-Endemic and Multiethnic Country
  • Abstract Number: 2322
    Gender-related Differences in Peripheral and Axial Spondyloarthritis
  • Abstract Number: 1063
    Gender, Racial, and Geographic Trends in Mortality from Interstitial Lung Diseases Among Patients With Rheumatoid Arthritis in the U.S. Population, 1999–2020
  • Abstract Number: 1701
    Gene Editing of HLA-Class II DRB1*04:01 at Position 82 Abrogates Binding of Citrullinated Arthritogenic Peptides and Collagen
  • Abstract Number: 2260
    Generative AI model identifies patients with Rheumatoid Arthritis (RA) months prior the diagnosis date: results from a large real-world RA cohort
  • Abstract Number: 0532
    Generative artificial intelligence provides synthetic data to discriminate patients with seronegative rheumatoid arthritis versus psoriatic arthritis sine psoriasis
  • Abstract Number: 1423
    Genetic and Cytokine Correlates in Ankylosing Spondylitis: rs27038 polymorphism of ERAP1 gene and IL-17 Interactions : A Case-Control Study
  • Abstract Number: 0174
    Genetic and Environmental Risk Factors and Incident Rheumatoid Arthritis
  • Abstract Number: 1523
    Genetic architecture and translational insights for SLE progression from preclinical stages
  • Abstract Number: 1197
    Genetic Profiling of Idiopathic Inflammatory Myopathies in Indian Patients Reveals Genotype-Phenotype Correlation
  • Abstract Number: 0045
    Genetic regulators of corticosteroid response in hepatic and adipose tissue and risk of adverse metabolic outcomes in patients with rheumatoid arthritis initiating glucocorticoids.
  • Abstract Number: 0593
    Genetic Risk Profiles Predict Clinical Heterogeneity in Systemic Lupus Erythematosus
  • Abstract Number: 0022
    Genome-wide association study identifies novel genetic risk factors for rheumatoid arthritis-associated interstitial lung disease
  • Abstract Number: 1823
    Genome-Wide DNA Methylation Analysis in Familial Mediterranean Fever
  • Abstract Number: 0970
    Genomic instability in systemic sclerosis is promoted by metabolic remodelling via a FOXO1-dependent axis
  • Abstract Number: 0167
    Geographic and Demographic Patterns of Rheumatoid Arthritis in the United States: Insights from GBD 2021
  • Abstract Number: 1891
    Geographic Trends in the Burden of Gout in the United States from 1990 to 2021: A State-Level Analysis of Prevalence, Incidence, and Disability
  • Abstract Number: 2475
    GERD Severity, Proton Pump Inhibitor Use, and Longitudinal Forced Vital Capacity in the CONQUER Registry
  • Abstract Number: 0743
    Giant Cell Arteritis Relapse After Treatment with Two Months of Prednisone and 12 Months of Tocilizumab
  • Abstract Number: 2153
    Giant Coronaries in Children with Kawasaki Disease: A Single Centre Experience
  • Abstract Number: 1868
    Global Downregulation of Fli1 in Mice Induces Cardiac Dysfunction via Enhanced β-fatty acid Oxidation and Collagen Deposition
  • Abstract Number: 0695
    Global Longitudinal, Circumferential, and Radial Strain in Systemic Sclerosis Patients with Left Ventricular Dysfunction
  • Abstract Number: 0445
    GLP-1 Receptor Agonists Reduce Mortality and Cardiovascular Events in Patients with Rheumatoid Arthritis
  • Abstract Number: 1027
    GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry
  • Abstract Number: 0319
    Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis
  • Abstract Number: 2687
    Glucagon-like peptide-1 receptor agonists therapy is associated in improvement in psoriatic arthritis-related and metabolic outcomes: A retrospective analysis of two cohorts
  • Abstract Number: 0734
    Glucocorticoid Exposure and Comorbidity Profile in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: a multi-country cohort study
  • Abstract Number: 0284
    Glucocorticoid Tapering and Relapse Risk in Anti-ARS Antibody-Positive Myositis: A Retrospective Study in a Single-Center Cohort Treated with Immunosuppressants
  • Abstract Number: 0668
    Glucocorticoid-Sparing Effects and Flare Suppression: Metformin Versus SGLT2 Inhibitors in Systemic Lupus Erythematosus
  • Abstract Number: 1860
    GLUT and FAPα as molecular imaging markers for interstitial lung disease in systemic sclerosis
  • Abstract Number: 0096
    GLUT1-Dependent Targeting and Enhanced Selectivity of a Glucose-Methotrexate Conjugate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
  • Abstract Number: 0981
    GNTI-350: A CAR-Treg Therapy Offering Durable Immune Reset with Improved Safety for B Cell–Driven Autoimmune Diseases
  • Abstract Number: 1143
    Gout and Renal Failure-Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
  • Abstract Number: 1596
    GPA-Associated Tracheobronchial Stenosis: Immunosuppressant Use and Dilation Frequency
  • Abstract Number: 1777
    Granzyme B as a regulator of interferon alpha production in cutaneous lupus erythematosus
  • Abstract Number: 0890
    Granzyme K+ CD8 T cells colocalize with myeloid cells and activate them through several pathways
  • Abstract Number: 2500
    Greater Economic Burden and Healthcare Resource Utilization in Patients with Systemic Sclerosis With Versus Without Interstitial Lung Disease: Results from a Systematic Literature Review
  • Abstract Number: 0354
    Greater Neighborhood Walkability is Associated with Lower Incidence of Hip Fracture in Older, Community-dwelling Women in the United States: The Cardiovascular Health Study
  • Abstract Number: 0364
    Group-Based Medical Mistrust and Logistical Factors Influencing Rheumatology Clinical Trial Enrollment: A Single-Center Cross-Sectional Survey
  • Abstract Number: 0836
    Growth Differentiation Factor-15 Predicts Frailty and Death in Rheumatoid Arthritis
  • Abstract Number: 1526
    Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project
  • Abstract Number: 2639
    Gut Microbiome Signatures Forecast Clinical Response to Methotrexate in Treatment-Naïve Early Rheumatoid Arthritis
  • Abstract Number: 0517
    Gut Microbiota Dysbiosis and Clinical Predictors of Fatigue in Primary Sjögren’s Syndrome: A Multi-Omics Study
  • Abstract Number: 1653
    Gut-joint lymphocyte trafficking functions to regulate systemic immunity
Jump to:  View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology